RNS Number : 9613X
Oxford Biomedica PLC
01 July 2008
For Immediate Release 1 JULY 2008
OXFORD BIOMEDICA ANNOUNCES UPDATE ON BOARD CHANGES
Oxford, UK - 1 July 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company,
announces today that changes to its Board of
Directors, which were announced on 15 April 2008, have become effective. The Company also
announces today the promotion of Nick Woolf to
Chief Business Officer, effective immediately. These changes reflect the Company's stage of
growth and are aligned with its strategic focus
on clinical development and commercialisation of its lead drug candidates.
Nick Woolf, Oxford BioMedica's Senior Vice President, Corporate Strategy, is appointed to
the newly created position of Chief Business
Officer. In this role, Nick will manage the Company's business activities, including
partnering, strategic transactions, capital markets and
investor relations. He joined Oxford BioMedica in 2002 and became an Executive Director in
2005. Prior to Oxford BioMedica, Nick was
Director and Head of European Biotechnology Research at ABN AMRO and was previously at
Robertson Stephens, Nomura and SBC Warburg.
In relation to Stuart Naylor's appointment to the Board, as per the announcement dated 15
April 2008, there are no further details
requiring disclosure under Paragraph 9.6.13 R of the Financial Services Authority Listing
Rules.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
Mike McDonald, Chief Executive Officer Tel: +44 (0)1865 783 000
Nick Woolf, Chief Business Officer
JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Tel: +44 (0)20 7466 5000
Johnson Buchanan Communications
Scientific/Trade Press Enquiries:
Holly Griffiths/ Katja Stout/ Claire Mosley Tel: +44 (0)20 7457 2020
College Hill Life Sciences
US Enquiries:
Thomas Fechtner Tel: (646) 378 2900
The Trout Group LLC
Notes to editors
Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer
immunotherapy and gene-based therapies. The Company
was established in 1995, as a spin-out from Oxford University, and is listed on the London
Stock Exchange.
The Company has a platform of gene delivery technologies, which are based on highly
engineered viral systems. Oxford BioMedica also has
in-house clinical, regulatory and manufacturing know-how. The lead product candidate is
TroVax®, a therapeutic vaccine for multiple solid
cancers, which is licensed to sanofi-aventis for global development and commercialisation.TroVax is in Phase III development. Oxford
BioMedica has three other products in clinical development, including ProSavin®, a novel
gene-based treatment for Parkinson's disease, in a
Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one
of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with
sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and
Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.
Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
FURSDLFUSSASEFM
|